The University of Queensland’s BASE facility – within the Australian Institute for Bioengineering and Nanotechnology (AIBN) – and Brisbane-based biotechnology company Vaxxas have been announced as stage winners of a prestigious global prize to accelerate a patch-based mRNA vaccine for COVID-19.
GSK’s RSV vaccine Arexvy shows long-term protection in Phase 3 trial
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS